摘要
目的探讨25羟基维生素D(25-hydroxylvitamin D,25OHD)、纤维蛋白原(Fibrinogen,Fbg)及D-二聚体(D-Dimer,D-D)联合检测对类风湿性关节炎(Rheumatoid arthritis,RA)的诊断价值。方法回顾性分析2018年1月~2019年1月期间于我院确诊为骨质增生的35例患者的临床资料纳入对照组,回顾性分析同期确诊为RA的35例患者的临床资料纳入观察组,所有入选者均已检测25OHD、Fbg及D-D水平,评估上述指标单项检测及联合检测的诊断价值。结果观察组患者250HD水平低于对照组患者,Fbg及D-D水平均高于对照组患者,差异有统计学意义(P<0.05);不同DAS-28评级RA患者中,缓解期250HD水平最高,而后由高至低依次为低度疾病活动期、中度疾病活动期、高度疾病活动期患者,组间比较,差异有统计学意义(P<0.05);不同DAS-28评级RA患者中,缓解期Fbg及D-D水平最低,而后由低至高依次为低度疾病活动期、中度疾病活动期、高度疾病活动期患者,组间比较,差异有统计学意义(P<0.05)。结论D-D、Fbg、25OHD检测对RA具有较高诊断价值,有助于判断患者病情及预后,值得临床推广应用。
Objective:To investigate the diagnostic value of combined detection of 25-hydroxylvitamin D(25 OHD),fibrinogen(Fbg)and D-dimer(D-D)in rheumatoid arthritis(RA).Methods The clinical data of 35 patients who were diagnosed as hyperostosis in our hospital from January 2018 to January 2019 were retrospectively analyzed and included in the control group,and the clinical data of 35 patients who were diagnosed as RA at the same period were retrospectively analyzed and included in the observation group.The levels of 25 OHD,Fbg and D-D of all selected patients were detected.The diagnostic value of single detection and joint detection was evaluated.Results The level of 25 OHD in observation group was lower than that in control group,and the levels of Fbg and D-D in observation group were higher than those in control group(P<0.05);Among the RA patients with different DAS-28 rating,the level of 25 OHD in remission stage was the highest,followed by low active group,medium active group and high active group,compared among groups,the difference was statistically significant(P<0.05);Among the RA patients with different DAS-28 rating,the levels of Fbg and D-D in remission stage were the highest,followed by low active group,medium active group and high active group,compared among groups,the difference was statistically significant(P<0.05).Conclusion:The detection of D-D,Fbg and 25 OHD has higher diagnostic value in RA,it is helpful to judge the disease condition and prognosis of patients,which is worthy of clinical promotion and application.
作者
李培培
Pei-pei LI(Department of Medical Laboratory,Xinyang First People’s Hospital,Xinyang,Henan 464000,China)
出处
《西藏医药》
2021年第2期13-15,共3页
Tibetan Medicine